Maalox mini

Quick links to important sections

Maalox mini

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maalox mini

Quick Facts

Property Description
Active ingredients Aluminum Hydroxide, Magnesium Hydroxide
Form Oral Suspension (Liquid Sachet)
Pharmacological class Neutralizing Antacid, Gastrointestinal Agent
Common purpose Relief from discomfort due to excess stomach acid
Origin Synthetic/Inorganic

The Pharmaceutical Identity and Class of Maalox mini

Maalox mini is an Over-The-Counter (OTC) combination antacid, which is classified as a neutralizing gastrointestinal agent. Its pharmaceutical identity is established by its two active ingredients: Aluminum Hydroxide and Magnesium Hydroxide, both of which are synthetic, inorganic metallic salts. This formulation is clinically recognized for its efficacy in immediate gastric acid neutralization.

The strategic formulation as a combination drug is a key differentiator from single-entity preparations. Aluminum Hydroxide tends to be mildly constipating, whereas Magnesium Hydroxide is classified as a saline laxative. This intentional pairing aims to provide balanced relief while mitigating potential side effects on normal bowel function. This non-systemic approach makes the product suitable for adults and adolescents seeking relief from typical acid-related discomfort, such as occasional heartburn.

Physical Form and General Function (Oral Suspension)

The pharmaceutical presentation of Maalox mini is an oral suspension, a ready-to-use liquid where the active ingredients are finely dispersed in an aqueous vehicle base. The "mini" designation refers to the convenient physical form: a single-dose liquid sachet. This format facilitates portability and ensures a measured dose is available for immediate oral ingestion, making it a distinctive option for patients requiring relief while mobile.

The product's general function is direct acid neutralization. Upon ingestion, the basic metallic hydroxides react immediately with the excess hydrochloric acid present in the stomach, chemically consuming the acid and causing a rapid increase in gastric pH. This swift local action is clinically recognized for providing immediate symptomatic relief by reducing the concentration of the irritant acid, thereby alleviating the general feelings of sourness and discomfort associated with hyperacidity.

Regulatory References

  1. Aluminum Hydroxide and Magnesium Hydroxide Antacids

What side effects are possible with Maalox mini?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and essential safety restrictions for Maalox mini formulations, based on official government regulatory documents.

Adverse Reactions

The officially documented side effects primarily involve the gastrointestinal system and mineral balance, categorized by frequency:

  • Uncommon (affecting up to 1 in 100 people):
    • Constipation
    • Diarrhoea
  • Very Rare (affecting less than 1 in 10,000 people):
    • Hypermagnesemia (high magnesium levels, particularly with prolonged use in patients with kidney problems).
  • Frequency Not Known (cannot be estimated from available data):
    • Hypersensitivity reactions (allergic reactions such as itching, hives, or swelling).
    • Hypophosphatemia (low phosphate levels).
    • Hyperaluminemia (high aluminum levels).

Serious and Clinically Significant Safety Concerns

Certain risks are flagged in official labeling, primarily relating to underlying health conditions and duration of use:

  • Risks in Kidney Impairment: The most significant safety concern is the accumulation of magnesium and aluminum, which is formally linked in regulatory documents to potentially severe neurological and skeletal issues, including encephalopathy, dementia, and worsening of bone disorders, especially with long-term exposure.
  • Risks with Prolonged Use: Extended use or high doses can cause a deficiency of phosphate (Hypophosphatemia), potentially leading to bone softening (osteomalacia).

Safety Restrictions and Contraindications

The medicine is strictly contraindicated (must not be used) in patients with severe kidney failure due to the risk of mineral accumulation. It is also restricted in cases of severe debilitation, known hypersensitivity to the ingredients, or in the presence of severe abdominal pain or suspected bowel obstruction. Use requires caution in patients with kidney disease, in the elderly, and in infants due to increased risk of complications, including intestinal obstruction with large doses.

Overdose and Emergency Response

The official overdose profile for this combination antacid primarily describes both acute gastrointestinal symptoms and severe systemic risks associated with chronic high-dose exposure. Acute overdose manifestations reported in regulatory documents include diarrhoea, abdominal pain, and vomiting. Serious symptoms are generally considered unlikely following a single acute overdosage.

However, prolonged use or high doses can lead to systemic toxicity, notably hypermagnesemia and hyperaluminemia, particularly in patients with renal impairment where the metallic salts are not effectively eliminated. Long-term accumulation in these at-risk populations may result in serious neurological outcomes like encephalopathy and dementia, or metabolic issues such as hypophosphatemia and osteomalacia. Large doses may also trigger or aggravate intestinal obstruction or ileus, especially in the elderly.

When to Seek Help: If an overdose is suspected, medical attention must be sought immediately. Consult a doctor or go to a hospital straight away if symptoms suggest an obstruction of the bowel or if other severe manifestations occur. There is no specific antidote known; treatment focuses on supportive care, including rehydration, forced diuresis, and the administration of IV Calcium Gluconate. In cases of renal function deficiency, regulatory guidance states that haemodialysis or peritoneal dialysis is necessary.

Therapeutic Uses of Maalox mini

The therapeutic scope of Maalox mini is used to provide supportive relief from the symptoms related to excess gastric acid.

Relief from Epigastric Burning and Acidic Regurgitation

This antacid combination is commonly used to help with symptoms related to physical discomfort caused by excess stomach acid. This medication is applied in therapeutic contexts where discomfort is driven by gastric hyperacidity, which results in the painful burning sensation of heartburn and the unpleasant sour taste associated with acid rising. The therapeutic uses include managing symptoms of acid indigestion, sour stomach, and upset stomach related to these manifestations. It is relevant for easing these acute manifestations and may provide support that helps ease the overall symptom load during periods of heightened discomfort.

“It is relevant for easing these acute manifestations and may provide support that helps ease the overall symptom load.”

Management of Occasional Acid Indigestion (Dyspepsia)

Maalox mini is commonly used across conditions presenting with episodic or fluctuating symptom patterns, such as non-ulcer dyspepsia or mild, intermittent reflux. It is applied during phases when symptoms become more noticeable, offering temporary assistance in symptom management and supports patients during difficult episodes by easing distress. The product is generally relevant when short-term symptomatic assistance is needed, such as when symptoms suddenly escalate following a large meal or manifest as nocturnal acid discomfort.


Quick Fact: Relief for Acute Acid Symptoms

Symptom Category Context of Use Primary Benefit
Symptoms related to Physical Discomfort Acute, on-demand episodes Provides support that helps ease the overall symptom burden
Episodic Reflux Following dietary indiscretion Assists with maintaining a sense of stability
Gastric Discomfort When symptoms interfere with routine Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

The official population eligibility for Maalox mini (Aluminum Hydroxide/Magnesium Hydroxide) is strictly defined by regulatory documents, primarily based on age, organ function, and pre-existing medical conditions.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Adolescents (typically age 14 years and older) are approved for standard use.
Populations for whom use is not recommended Children less than 14 years of age are generally not recommended to use the medicine.
Populations for whom use is contraindicated Patients with severe renal insufficiency or kidney failure, hypophosphataemia (low phosphate levels), or a known hypersensitivity to any component must not use the medicine.

Condition-Specific Eligibility Rules

Category Regulatory Restriction
Renal Function Status The medicine is contraindicated in severe kidney failure. Caution is required for non-severe impaired renal function, and prolonged high-dose use must be avoided.
Pregnancy and Lactation Pregnancy mandates caution, and prolonged high-dose use should be avoided; safety has not been established. Use during breastfeeding is generally considered compatible at recommended doses.
Other Conditions The medicine requires caution in patients who are severely debilitated, on a low-phosphorus diet, or have conditions like porphyria undergoing hemodialysis.

Connection to the overall eligibility profile

Regulatory documents define the primary eligible users as Adults and Adolescents. The most critical prohibitions are tied to the body's ability to clear the metallic salts, specifically severe kidney impairment. These official classifications of contraindicated and not recommended strictly establish the boundaries of approved use based on a patient's underlying health status and age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Maalox mini emphasizes a pharmacokinetic interaction where the antacid can significantly alter the absorption of co-administered medicines. This effect is driven by the metallic ions, Aluminum and Magnesium, which bind to other drugs (chelation) and alter the stomach's pH.

Documented Exposure Modification

Co-administration with numerous oral medicinal products, including tetracyclines, fluoroquinolones (e.g., ciprofloxacin), digoxin, bisphosphonates, and atenolol, may lead to a decreased plasma concentration of the co-administered drug. This reduction in exposure is formally addressed by timing constraints.

Conversely, citrate-containing products (such as certain fruit juices) are officially noted to enhance the gastrointestinal absorption and systemic exposure of aluminum.

Administration Restrictions

Regulatory labels mandate a specific separation of administration:

  • General Rule: At least 2 hours between the antacid and most orally administered medicines.
  • Fluoroquinolones: A more restrictive separation of at least 4 hours is required.

Furthermore, combination with specific Integrase Inhibitors (e.g., dolutegravir, raltegravir) is formally designated with a restriction requiring avoidance or strict timing that prevents effective co-administration.

Population-Specific Considerations

In patients with renal impairment, official documentation highlights an increased risk of aluminum toxicity and magnesium accumulation (hypermagnesemia) due to the reduced ability of the kidneys to clear the metallic ions. The risk of hypophosphatemia is also relevant for individuals on long-term use or low-phosphorus diets.

Mechanism of Action

Maalox Mini contains aluminum hydroxide, magnesium hydroxide, and simethicone, which exert effects within two primary mechanistic domains within the upper gastrointestinal tract.


Direct Chemical Neutralization of Gastric Acid

This domain involves the active ingredients aluminum and magnesium hydroxides. These compounds act as bases that directly react with hydrochloric acid (HCl) in the gastric lumen to produce water and neutral salts. This chemical cascade rapidly elevates the stomach's pH value within the gastric lumen.


Modulation of Mucosal Components and Luminal Gas Dynamics

This domain addresses the mucosal and luminal environment. Aluminum hydroxide may promote the generation of endogenous prostaglandins, which influences the structural properties of the gastric mucosal layer. Additionally, simethicone engages a non-absorbable mechanism by lowering the surface tension of intraluminal gas bubbles. This action alters the physical properties of trapped gas, facilitating the coalescence and expulsion of small air bubbles.

Dosage and Administration Information

Official Administration Guidelines

Maalox mini is an oral suspension administered strictly by the oral route for short-term, intermittent use. The usage protocol is defined by specific volume guidelines, timing relative to meals, and limitations on overall duration.


Administration Scope

Instruction Detail
Route of administration Oral.
Dosing schedule (Adults) A standard dose is 10 mL to 20 mL (two to four 5 mL units). The maximum permitted intake is 80 mL (16 teaspoons) in a 24-hour period.
Timing in relation to meals Doses are typically administered 20 minutes to one hour after meals and at bedtime, or as required.
Preparation requirements The suspension must be shaken well before use. It may be taken undiluted or consumed with water or milk, if necessary.
Age-group administration rules Use is generally restricted to adults and adolescents (typically aged 12 to 14 years and older). Use in children younger than this specified age range requires consultation.
Special procedural conditions Use of the maximum daily dosage must not exceed a continuous period of two weeks.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral suspension ingestion.
Frequency pattern As-needed (PRN) for acute symptoms, limited to a maximum of four times per day.
Use-context constraints Defined as an episodic, short-term treatment with an explicit limit on continuous maximum-dose use.

Connection to the Overall Use Protocol

The official instructions structure the use of the drug as an immediate-action, oral agent, defining clear volume, frequency, and timing parameters. The requirement to shake the suspension ensures accurate dosing, while the explicit time limit on continuous maximum use (two weeks) formalizes its intended role for short-term symptomatic relief.

Recent Clinical Evidence

Recent Clinical Evidence

Maalox mini contains a combination of aluminum hydroxide and magnesium hydroxide, which function as antacids by neutralizing hydrochloric acid in the stomach. Clinical data on this combination focus on its effects on gastric acidity and relief of symptoms associated with hyperacidity.


Efficacy and Symptomatic Relief

Research has explored the acid-neutralizing capacity of aluminum and magnesium hydroxide mixtures, confirming that they increase gastric pH. This action is associated with the relief of symptoms in conditions such as heartburn, acid indigestion, and upset stomach.

  • Onset and Duration: Studies comparing different antacid formulations indicate that liquid suspensions, such as Maalox mini, generally demonstrate a rapid onset of acid neutralization. However, the duration of effect for non-systemic antacids is generally short, necessitating repeated dosing for sustained relief.

  • Combination Effect: The combination of aluminum hydroxide and magnesium hydroxide is designed to balance common side effects. Aluminum salts tend to cause constipation, while magnesium salts may induce diarrhea. Combining them helps mitigate the pronounced effect of either ingredient alone on bowel motility.


Safety and Tolerability

Studies tracking the safety profile show that the antacid combination is generally well-tolerated. Systemic absorption of the active ingredients is low in individuals with normal kidney function.

Common Study Observations Notes
Gastrointestinal Effects Reported side effects include changes in bowel habits (e.g., diarrhea or constipation).
Interactions The neutralizing effect on stomach acid may reduce the absorption of several oral medications, including certain antibiotics (e.g., tetracyclines, fluoroquinolones) and thyroid hormones.
Renal Impairment In patients with severe kidney disease, the systemic accumulation of aluminum or magnesium remains a key clinical consideration and requires caution.

Frequently Asked Questions (FAQ)

Common questions about Maalox mini (FAQ)

Q: How quickly should I expect Maalox mini to relieve my heartburn symptoms?

A: Studies and official product information indicate that liquid antacid suspensions, such as this product, typically demonstrate a rapid onset of acid neutralization. This fast action is often associated with symptomatic relief that may begin within minutes of taking the dose.


Q: How is Maalox mini different from the standard Maalox liquid suspension?

A: The 'mini' designation refers to the specific physical form: a single-dose liquid sachet. This format ensures a measured dose of the active ingredients, which are the same aluminum and magnesium hydroxides found in other liquid antacid suspensions.


Q: Why does Maalox mini sometimes cause constipation?

A: The active ingredient aluminum hydroxide has what are called astringent properties. This means it may slow down natural bowel movements, which can lead to the side effect of constipation.


Q: Is it true that some Maalox products can cause diarrhea?

A: One of the active ingredients, magnesium hydroxide, is classified in regulatory documents as a saline laxative. This action may cause a drawing of water into the intestines, which can lead to the potential side effect of diarrhea.


Q: What is the difference between Maalox mini and other antacids like Tums or Rolaids?

A: Maalox mini is defined as a combination antacid because it contains two active ingredients: aluminum hydroxide and magnesium hydroxide. This differs from other products that may be single-ingredient antacids, such as those that only use calcium carbonate.


Q: Is Maalox mini appropriate for use during pregnancy?

A: Official regulatory labels advise that caution is required if the medicine is used during pregnancy. Prolonged use or high doses of the product should be avoided, and official documentation notes that consultation with a health professional is a requirement for use.


Q: Can Maalox mini mask the symptoms of a more serious underlying stomach condition, such as an ulcer?

A: Official safety warnings state that antacids provide symptomatic relief, but prolonged use may mask the symptoms of more serious diseases, such as gastrointestinal ulceration or cancer. The regulatory warning indicates that if symptoms persist for more than two weeks, a health professional should be consulted.


Q: What is the role of simethicone in the Maalox mini formulation?

A: Simethicone is classified as an antiflatulent, an agent that helps manage gas. It works by lowering the surface tension of gas bubbles in the stomach and intestine, which helps them combine and pass easily to relieve feelings of bloating and gas.


Q: Does Maalox mini contain any sugars or sweeteners that could affect people with diabetes?

A: Some Maalox formulations contain sorbitol (a sugar alcohol) and other excipients (inactive ingredients). Official labeling specifically notes that this medicine is restricted for use in patients with rare hereditary problems of fructose intolerance.


Q: Does Maalox mini lose effectiveness if used too often?

A: Regulatory documents do not describe a loss of effectiveness, but they do set an explicit safety limit on the continuous use of the maximum dose to two weeks. Use beyond this time requires medical evaluation.


Q: Can Maalox mini be safely used if a person has diagnosed Irritable Bowel Syndrome (IBS)?

A: Official regulatory documents note that caution is required in patients with inflammatory bowel disease or risk of intestinal obstruction. For patients with pre-existing conditions affecting the digestive system, regulatory documents indicate that caution or further medical evaluation is required.


Q: What is the recommended period of time for continuous use of Maalox mini before speaking to a professional?

A: Official product labeling contains a warning that if symptoms last for more than 2 weeks, discontinuation of use and medical consultation are necessary.


Q: Is it possible to have an allergic reaction to one of the inactive ingredients?

A: Hypersensitivity reactions (allergic reactions) are listed in official documents as a possible side effect. The official product information on inactive ingredients notes that some excipients, such as sulphur dioxide, may rarely cause these reactions.


Q: Does Maalox mini treat the cause of acid reflux or just the symptoms?

A: According to the official mechanism of action, Maalox mini provides rapid, symptomatic relief by neutralizing excess acid already present in the stomach. It does not treat or suppress the underlying cause of acid production or reflux.


Q: Is Maalox mini effective for treating general upset stomach or only heartburn?

A: The medicine is approved for the relief of discomfort due to excess stomach acid and is indicated for a range of symptoms, including heartburn, acid indigestion, sour stomach, and general upset stomach.


Q: Are there any non-prescription medicines that should not be taken near the time of taking Maalox mini?

A: While regulatory documents focus on spacing for specific prescription drugs, the general mechanism of action means antacids may interact with many orally administered medicines. Given the potential for interaction, official labels emphasize the importance of consulting a health professional about taking any co-administered medicine.


Q: Can consuming milk or dairy products affect how Maalox mini works?

A: Official regulatory labels issue a primary interaction warning regarding citrate-containing products (like certain fruit juices) which can enhance the absorption of aluminum. Milk or dairy products are not typically listed as interacting substances in the product documentation.


Q: What is the recommendation for taking Maalox mini with alcohol?

A: Official regulatory documents do not provide a specific recommendation or warning against combining the medicine with alcohol. However, some Maalox formulations contain small amounts of ethanol (alcohol) in the inactive ingredients.


Q: Can Maalox mini affect the way iron supplements are absorbed?

A: Antacids can alter the stomach's pH and bind to other compounds, which can reduce the absorption of various orally administered medications. Due to this risk, the strategy of separating the timing of the antacid dose and other oral medications, including iron supplements, is commonly employed.


Q: Are there different Maalox products that users often confuse with Maalox mini?

A: The FDA has issued warnings regarding consumer confusion between traditional Maalox antacid products and a distinct variant, Maalox Total Relief. This variant contains a different active ingredient (bismuth subsalicylate) and is not the same as the aluminum/magnesium formulation.


Q: Is Maalox mini used to manage symptoms of ulcers?

A: The medicine is officially indicated for the symptomatic relief of hyperacidity. The regulatory warning that prolonged use may mask the symptoms of more serious diseases, such as gastrointestinal ulceration, limits its role in managing conditions like ulcers.


Q: Is Maalox mini suitable for use on a low-salt diet?

A: According to official documentation, some Maalox formulations are described as containing less than 1 mmol sodium (23 mg) per dose. This quantity is considered to be essentially 'sodium-free'.


Q: Does the formulation of Maalox mini contain sodium?

A: The formulation contains sodium, but regulatory documents state that some versions contain less than 1 mmol sodium (23 mg) per dose. This quantity is described as being essentially 'sodium-free'.


Q: Does the product have an expiry date, and is it still safe to use after that date?

A: Official documentation specifies a shelf life for the unopened product, which is indicated by the expiry date. Additionally, some official labels require the product to be disposed of six months after first opening, regardless of the printed expiration date.

How should Maalox mini be stored and disposed of?

Storage and Disposal Requirements for Maalox Mini

Official regulatory labeling dictates the specific conditions necessary for storing and discarding the Maalox Mini oral suspension.


Storage Conditions

This medicine must be stored at controlled room temperature, maintaining a range of 20°C to 25°C (68°F to 77°F). The product must be protected from freezing to preserve the integrity of the suspension. The container should be kept tightly closed, and the medicine must always be stored out of the reach and sight of children.

Stability and Disposal

Some official labels require disposal of the product six months after first opening, regardless of the marked expiration date. For disposal, the medicine must not be thrown away via wastewater or household trash. Unused or expired product should be taken to a drug take-back location or the patient should ask a pharmacist for disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maalox mini found in:

A-Z Index: